$14.31
1.04% yesterday
NYSE, Dec 02, 10:00 pm CET
ISIN
US8740602052
Symbol
TAK

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock price

$14.29
+0.87 6.48% 1M
-0.79 5.24% 6M
+1.05 7.93% YTD
+0.43 3.10% 1Y
-0.53 3.58% 3Y
-4.05 22.08% 5Y
-10.10 41.41% 10Y
-13.06 47.75% 20Y
NYSE, Closing price Tue, Dec 02 2025
-0.17 1.18%
ISIN
US8740602052
Symbol
TAK
Industry

Key metrics

Basic
Market capitalization
$45.8b
Enterprise Value
$70.9b
Net debt
$25.1b
Cash
$4.7b
Shares outstanding
1.6b
Valuation (TTM | estimate)
P/E
109.9 | 15.3
P/S
1.6 | 1.6
EV/Sales
2.5 | 2.4
EV/FCF
12.0
P/B
1.0
Dividends
DPS
$0.67
Yield 1Y | 5Y
4.7% | 4.5%
Growth 1Y | 5Y
8.8% | -4.3%
Payout 1Y | 3Y
151.2% | 82.2%
Increased
1 Year
Financials (TTM | estimate)
Revenue
$28.3b | $29.4b
EBITDA
$5.9b | $8.0b
EBIT
$2.4b | $2.6b
Net Income
$212.2m | $1.5b
Free Cash Flow
$5.9b
Growth (TTM | estimate)
Revenue
-2.8% | 0.0%
EBITDA
-15.3% | 13.1%
EBIT
-31.1% | -25.2%
Net Income
-88.6% | 112.5%
Free Cash Flow
72.0%
Margin (TTM | estimate)
Gross
64.6%
EBITDA
20.8% | 27.2%
EBIT
8.5%
Net
0.8% | 5.0%
Free Cash Flow
20.9%
Financial Health
Equity Ratio
48.7%
Return on Equity
1.6%
ROCE
3.0%
ROIC
1.1%
Debt/Equity
0.7
More
EPS
$0.1
FCF per Share
$3.7
Short interest
0.3%
Employees
49k
Rev per Employee
$600.0k
Show more

Is Takeda Pharmaceutical Co. Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,078 stocks worldwide.

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast:

10x Buy
53%
9x Hold
47%

Analyst Opinions

19 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast:

Buy
53%
Hold
47%

Financial data from Takeda Pharmaceutical Co. Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
28,335 28,335
3% 3%
100%
- Direct Costs 10,031 10,031
1% 1%
35%
18,304 18,304
5% 5%
65%
- Selling and Administrative Expenses 6,902 6,902
1% 1%
24%
- Research and Development Expense 4,436 4,436
5% 5%
16%
5,904 5,904
15% 15%
21%
- Depreciation and Amortization 3,508 3,508
0% 0%
12%
EBIT (Operating Income) EBIT 2,396 2,396
31% 31%
8%
Net Profit 212 212
89% 89%
1%

In millions USD.

Don't miss a Thing! We will send you all news about Takeda Pharmaceutical Co. Ltd. Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock News

Negative
Reuters
12 days ago
The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder drug, the health regulator said on Friday.
Neutral
GlobeNewsWire
14 days ago
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leading neurotechnology company powering AI-driven neurodiagnostics and precision medicines for the brain, today announced a multi-year expansion of its strategic collaboration with Takeda, which began in 2024. This extension leverages the Beacon Platform to accelerate data-driven development of sleep biomarkers and patterns, and su...
Neutral
Business Wire
26 days ago
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patien...
More Takeda Pharmaceutical Co. Ltd. Sponsored ADR News

Company Profile

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Head office Japan
CEO Christophe Weber
Employees 49,281
Founded 1781
Website www.takeda.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today